Ascendis Pharma A/S (NASDAQ:ASND) Reaches New 52-Week High After Analyst Upgrade

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) hit a new 52-week high during trading on Friday after Stifel Nicolaus raised their price target on the stock from $254.00 to $256.00. Stifel Nicolaus currently has a buy rating on the stock. Ascendis Pharma A/S traded as high as $229.94 and last traded at $220.3560, with a volume of 1088268 shares trading hands. The stock had previously closed at $210.16.Can BioMarin Stock Live Up to Wall Street’s High Expectations?A number of other analysts have also commented on the stock. Raymond James Financial started coverage on shares of Ascendis Pharma A/S in a research note on Friday, October 17th. They issued a "strong-buy" rating and a $271.00 price target for the company. Wall Street Zen lowered Ascendis Pharma A/S from a "buy" rating to a "hold" rating in a research note on Saturday, November 15th. Weiss Ratings restated a "sell (d-)" rating on shares of Ascendis Pharma A/S in a report on Wednesday, October 8th. Cantor Fitzgerald reissued an "overweight" rating on shares of Ascendis Pharma A/S in a research note on Wednesday, November 26th. Finally, Wolfe Research started coverage on Ascendis Pharma A/S in a research note on Tuesday, November 18th. They set a "peer perform" rating and a $255.00 price objective for the company. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $256.73.Get Ascendis Pharma A/S alerts:Check Out Our Latest Analysis on ASNDInstitutional Inflows and Outflows3 Oversold Stocks with Big RSI Rebound PotentialA number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Advisory Services Network LLC acquired a new position in Ascendis Pharma A/S in the 3rd quarter valued at $26,000. Compagnie Lombard Odier SCmA purchased a new stake in Ascendis Pharma A/S during the 2nd quarter worth approximately $39,000. Jones Financial Companies Lllp grew its holdings in Ascendis Pharma A/S by 57.2% during the 3rd quarter. Jones Financial Companies Lllp now owns 228 shares of the biotechnology company's stock worth $44,000 after acquiring an additional 83 shares in the last quarter. First Horizon Advisors Inc. purchased a new stake in Ascendis Pharma A/S during the second quarter worth approximately $41,000. Finally, Hantz Financial Services Inc. lifted its stake in Ascendis Pharma A/S by 291.1% in the second quarter. Hantz Financial Services Inc. now owns 352 shares of the biotechnology company's stock valued at $61,000 after buying an additional 262 shares during the last quarter. Ascendis Pharma A/S Stock PerformanceThe company has a 50-day moving average of $206.01 and a 200-day moving average of $190.73. The stock has a market cap of $13.59 billion, a price-to-earnings ratio of -49.63 and a beta of 0.45. Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its quarterly earnings data on Thursday, November 13th. The biotechnology company reported ($1.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.76). The business had revenue of $250.71 million for the quarter, compared to the consensus estimate of $246.91 million. As a group, equities research analysts forecast that Ascendis Pharma A/S will post -4.34 EPS for the current year. About Ascendis Pharma A/S (Get Free Report)Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.Read MoreFive stocks we like better than Ascendis Pharma A/SDiversification Can Smooth Returns And Mitigate Portfolio RiskCrowdStrike Stock Can't Catch a Break—Even After a Blowout QuarterHow to Calculate Inflation RateChewy Stock Just Flashed a Major Buy Signal for 2026NYSE Stocks Give Investors a Variety of Quality Options Broadcom Slips Post-Earnings Even as AI Demand Goes ParabolicThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Ascendis Pharma A/S Right Now?Before you consider Ascendis Pharma A/S, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ascendis Pharma A/S wasn't on the list.While Ascendis Pharma A/S currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here